Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Autor:	Camille F, Ng, John, Glaspy, Veronica R, Placencio-Hickok, Shant, Thomassian, Jun, Gong, Arsen, Osipov, Andrew E, Hendifar, Natalie, Moshayedi
Rok vydání:	2022
Předmět:	Pancreatic Neoplasms Oncology Quinoxalines Tumor Microenvironment Humans Pyrazoles Adenocarcinoma Receptor Fibroblast Growth Factor Type 2 Carcinoma Pancreatic Ductal
Zdroj:	Journal of the National Comprehensive Cancer Network. 20:1076-1079
ISSN:	1540-1413 1540-1405
Popis:	Despite advances in cancer therapeutics, pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest malignancies, with a poor prognosis at time of diagnosis. Research in PDAC has suggested that adaptive signaling in the tumor microenvironment may promote tumor proliferation and survival. Several FGFR fusion genes—specifically FGFR2—are involved with the creation and progression of cancer. These mutations are found in a variety of cancer types. This report presents a unique case of a young patient with stage IV PDAC with a known FGFR2 fusion. This molecular alteration afforded a remarkable response to FGFR inhibitor therapy, erdafitinib, after the patient experienced disease progression on multiple chemotherapy regimens.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8dd119b95cd9ff5b6afef80b4e7796b https://doi.org/10.6004/jnccn.2022.7039 Zobrazit plný text záznamu